B
IRWD icon

Bailard’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bailard’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,500
Closed -$140K – 748
2022
Q3 		$140K Hold
13,500
– – 0.01% 621
2022
Q2 		$156K Buy
+13,500
New +$159K 0.01% 630
2018
Q4 		– Sell
-34,029
Closed -$526K – 523
2018
Q3 		$526K Hold
34,029
– – 0.03% 360
2018
Q2 		$545K Buy
34,029
+6,567
+24% +$97.2K 0.03% 343
2018
Q1 		$355K Hold
27,462
– – 0.02% 392
2017
Q4 		$345K Buy
+27,462
New +$359K 0.02% 357

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's IRWD Position: Q4 2022 in Review

Bailard sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2022, closing a stake of 13,500 shares — an estimated $140K sold.

Bailard first reported a position in IRWD in Q4 2017 and held it in 6 quarters. The position peaked at $545K in Q2 2018. 250 funds tracked by Wall St. Rank hold IRWD as of Q4 2022.

  • Bailard reported no remaining Ironwood Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Bailard sold 13,500 Ironwood Pharmaceuticals shares in Q4 2022, an estimated $140K.
  • Bailard first reported a position in Ironwood Pharmaceuticals in Q4 2017 and held it in 6 quarters.
  • Bailard's Ironwood Pharmaceuticals position peaked at $545K in Q2 2018.
  • 250 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.